An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2
Cheng, z.; Zhang, D.; Liu, X.; Miao, J.; wang, J.; Guo, H.; Yan, W.; Zhang, Z.; Lu, S.; Zhang, N.; Wang, J.; Zhang, Z.; Liu, W.; Zhang, Y.; Zhang, L.; Dong, J.; Lemoine, N. R.; Wang, Y.
Show abstract
More than one hundred vaccines against SARS-CoV-2 have been developed and some of them have entered clinical trials, but the latest results revealed that these vaccines still face great challenges. Here, we developed a novel cell-based gp96-Ig-secreting chimeric vaccine which is composed of two viral antigens, the RBD of spike protein, and a truncated nucleocapsid protein that could induce epitope-specific cytotoxic T lymphocytes but low antibody response. Syrian hamsters immunized with the cell-based vaccine produced high level of SARS-CoV-2 specific NAbs and specific T cell immunity which could eliminate RBD-truncated N-expressing cells, without the induction of antibody against N protein and other observed toxicity. This study provides a proof of concept for clinical testing of this safe, effective and cost-effective vaccine against SARS-CoV2 infection.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Soluble Spike DNA vaccine provides long-term protective immunity against SAR-CoV-2 in mice and nonhuman primates 96%
- Oral immunization with rVSV bivalent vaccine elicits protective immune responses, including ADCC, against both SARS-CoV-2 and Influenza A viruses 96%
- Long-term Immunity of a Microneedle Array Patch of SARS-CoV-2 S1 Protein Subunit Vaccine Irradiated by Gamma Rays in Mice 95%
Similar papers in this journal
- Omicron booster in ancestral strain vaccinated mice augments protective immunities against both the Delta and Omicron variants 97%
- Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant. 96%
- Addressing SARS-CoV-2 Evolution: Neutralization of Emerging Variants of Concern by the AVX/COVID-12 'Patria' Vaccine Based on HexaPro-S Ancestral Wuhan Spike or Its Updated BA.2.75.2 Version 95%
Similar papers in this journal
- Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice 97%
- Recombinant SARS-CoV-2 RBD molecule with a T helper epitope as a built in adjuvant induces strong neutralization antibody response 95%
- VSA-2, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine 95%
Similar papers in this journal
- A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants 97%
- A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus 95%
- Evaluation of antibody kinetics and durability in health subjects vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China 95%
Similar papers in this journal
- Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 95%
- A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice 94%
- A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.